Combination of Anlotinib and PD-1/PD-L1 Inhibitors as Second-line and Subsequent Therapy in Advanced Small-cell Lung Cancer
JOURNAL OF THORACIC ONCOLOGY（2022）
Key words
small-cell lung cancer, anlotinib, PD-1/PD-L1
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined